Skip to main content
Premium Trial:

Request an Annual Quote

The Downside of Pharmacogenomics: Sorry, You May Be a Nonresponder

Studies published in the Lancet and the New England Journal of Medicine this week provide the basis for this article in the Wall Street Journal, which reports that "patients with a particular gene variant seem to respond less effectively to the anticlotting agent Plavix than those with the normal version of the gene." Researchers wonder whether higher doses of Plavix would make a difference for people with the variant, or whether the drug will simply be ineffective for them, noting that more studies are needed.

 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.